Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection | ePharma
0 Items

Leading Online Pharmacy, of Bangladesh

Home Medicines Cancer/oncology Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection

✔ 100% Authentic Product


Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection

Generic: Rituximab

Type: Injection

Pack Size: 1 Pc

Rituximab is indicated for the treatment of-

  • Non-Hodgkin lymphoma (NHL)
  • Rheumatoid arthritis
  • Chronic lymphocytic leukemia (blood cancer)
  • Granulomatosis with polyangiitis
  • Microscopic polyangiitis

🎁 Enjoy Special Cahback Offer

🩺 Free Doctor Consultation Offer

🩺 Doctor Consultation Package

How to Order

🛒 How to order this item?

Discount Price: ৳ 64320
MRP: ৳ 67000 4% Off

⪼ Save  ৳: 2680  in this Product

100% Genunie Product

Safe & Secure Payment

Secure & Effecient Delivery

Proper Packaging

Cashback offer(Optional):

  • Coupon CASH55 ✔️ Get ৳55 back - for Ordering ৳500+
  • Coupon CASH120 ✔️ Get ৳120 back - for Ordering ৳1200+
  • Coupon CASH200 ✔️ Get ৳200 back - for Ordering ৳2500+
  • Coupon CASH300 ✔️ Get ৳300 back - for Ordering ৳3500+
  • Coupon CASH400 ✔️ Get ৳400 back - for Ordering ৳4500+
  • Coupon CASH500 ✔️ Get ৳500 back - for Ordering ৳5500+
  • 🔹 Delivery charge is applicable for Cashback offer
  • 🔹 Foreign manufacturer products are not applicable for Cashback offer

  • Cash on Delivery - All over Bangladesh
  • Urgent Delivery - 2 Hours Dhaka City

  • ফ্রি ডেলিভারি! - ৯৯৯ টাকা+ অর্ডারে ঢাকা শহরে ।
  • ফ্রি ডেলিভারি! - ২৪৯৯ টাকা+ অর্ডারে ঢাকার বাহিরে ।


Non-Hodgkin’s Disease (Non-Hodgkin’s Lymphoma):

  • Non-Hodgkin's lymphoma is a type of blood cancer that affects the lymph system, causing the uncontrollable growth of cancer cells in the lymph nodes. Symptoms may include lymph node swelling, abdominal pain, chest pain, cough, fever, and night sweats. Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection is likely prescribed as part of the treatment for this condition.

Rheumatoid Arthritis:

  • Rheumatoid arthritis is an autoimmune disease where the body's immune system attacks its tissues, leading to joint pain and damage. Symptoms include pain, swelling, stiffness, joint deformities, and loss of joint function. Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection is used in combination with methotrexate for the treatment of rheumatoid arthritis.

Chronic Lymphocytic Leukemia (CLL):

  • Chronic lymphocytic leukemia is a type of cancer that originates in the bone marrow and affects the blood. It involves an increased number of lymphocytes, a type of white blood cell. Symptoms may include fever, enlarged liver, bone or joint pain, shortness of breath, weakness, and bleeding from gums, or easy bruising.

Pemphigus Vulgaris:

  • Pemphigus vulgaris is a condition characterized by painful blisters on the skin and the lining of the mouth, nose, throat, and genitals. It is an autoimmune disorder where the immune system mistakenly attacks healthy cells, leading to blister formation.

Safety Advices


Avoid consumption of alcohol while receiving Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection as it may make you feel drowsier.


The decision to use Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection during pregnancy should involve a thorough discussion between the patient and the doctor, weighing the potential benefits against the risks.


 the decision regarding breastfeeding should involve a discussion with the doctor. Depending on the clinical condition, the doctor might advise discontinuation of breastfeeding for a specific period or may suggest an alternative medicine.


It is highly unlikely that Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection will affect your ability to drive.


Inform your doctor before receiving Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection. Limited data suggests that dose adjustment of Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection may not be needed in patients with kidney disease. However, it's important to consult your doctor, who will determine the most appropriate course of action based on your condition.


Inform your doctor before receiving Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection. Depending on the pre-existing or historical liver condition, your doctor may consider a dose adjustment of Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection or suggest a suitable alternative.

Similar Products

Uses of Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection
  • Non-Hodgkin's Lymphoma
  • Chronic Lymphocytic Leukaemia
  • Rheumatoid Arthritis
  • Granulomatosis with polyangiitis and microscopic polyangiitis
How does Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection work?

It's a monoclonal antibody targeting unwanted activity of immune cells (B cells) in rheumatoid arthritis and certain cancers.

Side Effects of Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection
  • Headache
  • Weakness
  • Edema (swelling)
  • Infection
  • Hair loss
  • Itching
  • Chills
  • Febrile neutropenia
  • Decreased white blood cell count
  • Infusion reaction
  • Increased risk of infection
  • Decreased blood cells (red cells, white cells, and platelets)
Quick Suggestions:
  • Administered as an intravenous infusion by a healthcare professional.
  • Premedication may include painkillers, antihistamines, and possibly steroids to prevent infusion reactions.
  • Regular blood tests may be conducted to monitor hepatitis B and blood cell levels.
  • Immediate notification to the doctor if signs of infection like fever, sore throat, or rash occur.
  • Inform the doctor if pregnant, planning to conceive, breastfeeding, have heart rhythm problems, undergoing surgery, or planning vaccinations.Not recommended during pregnancy or while breastfeeding.
  • Effective contraception use during treatment is emphasized for both males and females.

Mabthera Injection is an anticancer medicine that is used for the treatment of blood cancers.

  • Target Antigen: CD20
  • Action:

Complement-Dependent B-cell Cytotoxicity (CDC): Rituximab binds to the CD20 antigen on the surface of B cells, leading to the activation of the complement system. This activation triggers a series of events that destroy the targeted B cells.

Antibody-Dependent Cellular Toxicity (ADCC): Rituximab also binds to human Fc receptors, engaging immune cells (such as natural killer cells) to recognize and destroy the cells marked with Rituximab. This process is known as antibody-dependent cellular toxicity.

This dual mechanism of action contributes to the elimination of B cells, which can be beneficial in conditions where aberrant B cell activity or overproduction is implicated, such as certain cancers and autoimmune disorders.

Dosage of Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection

Adult Dose:

Intravenous (IV) Administration:

Non-Hodgkin Lymphoma (NHL):

  • Recommended dose for NHL: 375 mg/m² IV infusion.

Specific Schedules for NHL Treatment:

Relapsed or refractory low-grade or follicular, CD20-positive, B-cell NHL:

  • Once weekly for 4-8 doses.

Retreatment for relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL:

  • Once weekly for 4 doses.

Previously untreated, follicular, CD20-positive, B-cell NHL:

  • Administer on Day 1 of each chemotherapy cycle for up to 8 doses.
  • With complete or partial response, initiate maintenance 8 weeks following completion of combination chemotherapy as a single-agent q8 weeks for 12 doses.

Nonprogressing, low-grade, CD20-positive, B-cell NHL, after first-line CVP chemotherapy:

  • Following completion of 6-8 cycles of CVP chemotherapy, administered once weekly for 4 doses at 6-month intervals to a maximum of 16 doses.

Diffuse large B-cell NHL:

  • Administer on Day 1 of each cycle of chemotherapy for up to 8 infusions.

Chronic Lymphocytic Leukemia (CLL):

  • Indicated for untreated and previously treated CD20-positive CLL; combined therapy with fludarabine and cyclophosphamide (FC):
    • 375 mg/m² IV infusion on day 1 of the 1st cycle (for the 1st cycle, administer 1 day before chemotherapy with FC).
    • THEN 500 mg/m² IV on day 1 of subsequent cycles (administered on the same day as chemotherapy with FC).
    • Repeat q28 days x 6 cycles.

Fludarabine & Cyclophosphamide Dosage for CLL:

  • Fludarabine: 25 mg/m² IV qDay x 3 days.
  • Cyclophosphamide: 250 mg/m² IV qDay x 3 days.
  • Repeat q28 days x 6 cycles.

Rheumatoid Arthritis:

  • 1000 mg IV infusion, repeat after 2 weeks (2 infusions separated by 2 weeks is 1 course).
  • Repeat course q24 weeks or based on clinical evaluation (but no sooner than 16 weeks).
  • Used in combo with methotrexate.
  • Premedicate with glucocorticoids 30 minutes before infusion to reduce infusion reaction.
  • Not to exceed 1000 mg/dose.

Child Dose:

  • Safety and efficacy not established.
Direction for use:
  • Given as an injection under the supervision of a doctor.
  • Dosage and frequency are determined by the treating doctor.
  • Should be taken exactly as prescribed to avoid serious side effects.

Before receiving Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection, it is crucial to inform your doctor about all the medicines, supplements, or herbals you are currently taking. Some medicines can interact with Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection, either affecting its efficacy or being affected by it. Here are some specific interactions to be aware of:

Interaction with Alcohol:

  • Interaction with alcohol is unknown. Consult your doctor before consumption.

Interaction with Other Medicines:

  • Medicines used to treat high blood pressure (atenolol, propranolol, amlodipine, enalapril, olmesartan, losartan)
  • Medicines that suppress immune functions (ciclosporin, tacrolimus)
  • Other anticancer medicines (Trastuzumab, Bevacizumab, Alemtuzumab, Cetuximab)


  • Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection will be administered only by a doctor or nurse in a hospital.
  • Unlikely to receive an overdose, but consult your doctor if you experience any unusual symptoms.
  • Lactation
  • Hypersensitivity or anaphylactic reactions to murine proteins or components of the formulation.
Pregnancy & Lactation

The pregnancy category C indicates that there are animal studies that have shown adverse effects on the fetus (teratogenic or embryotoxic), but there are no controlled studies in women, and the potential benefits of the drug may still warrant its use in pregnant women if there is a potential benefit to the fetus. It means that the decision to use the drug during pregnancy should be made considering the potential risks and benefits and should be discussed thoroughly between the patient and the healthcare provider.

It's crucial for pregnant women or those planning to become pregnant to consult with their healthcare provider before using any medication. The potential risks and benefits need to be carefully evaluated based on the individual's health condition and the specific circumstances.

Precautions & Warnings
  • Extensive tumor burden, pulmonary tumor infiltration, or pulmonary insufficiency
  • History of cardiac disease
  • Effective contraception during and up to 12 months after treatment
  • Pregnancy
  • Monitoring CBC and platelet counts regularly
  • Premedication with analgesics, antihistamines, and corticosteroids may be recommended
  • Monitoring for signs of active infection or hepatitis in hepatitis B carriers
  • Discontinue treatment if viral hepatitis develops
Storage Conditions

Store in a refrigerator (2 °C – 8 °C). Keep the container in the outer carton to protect it from light. Keep it out of the reach of children.

Frequently Asked Questions (FAQ)

The initial response to this medicine can be observed within 7 to 14 days of administration.

Mabthera contains Rituximab, which works by inhibiting the DNA and RNA transcription that is essential for cancer cell growth.

Mabthera should be used in children and adolescents (aged below 18 years) only if prescribed by the physician. Therefore, consult your doctor for advice before receiving it.
Ratings & Reviews

No review

Check our pricing section for Mabthera 1400mg/11.7ml Solution for Subcutaneous Injection price in Bangladesh. After Submitting Order, You will receive a phone call for verification, price and delivery confirmation. We deliver inside/outside Dhaka (Delivery all over Bangladesh). We offer express/urgent medicine delivery inside Dhaka. Do not forget to check discount/cashback offers if you are eligible to avail any.

ePharma sole intention is to ensure that its consumers get proper information as musch as possible. Although we do not guarantee the accuracy and the completeness of the information that provided and here information is for informational purposes only. The information contained herein should NOT be used as a substitute for the advice of a qualified physician. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your healthcare professional and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.

Pricing Information, Availability:
ePharma reserves the right to make adjustments to pricing, Products and Service offerings for reasons including, but not limited to, changing market conditions, Product discontinuation, Product unavailability, manufacturer price changes, supplier price changes and errors in advertisements. All orders are subject to Product availability and the availability of Personnel to perform the Services. Therefore, Seller cannot guarantee that it will be able to fulfill Customer’s orders. If Services are being performed on a time and materials basis, any estimates provided by Seller are for planning purposes only.

Hi, there!

Get more features!

Download the app now

  • Pill reminder
  • Prescription & Report
  • Doctor consultation
  • 24/7 helpline